Catalent Pharma Solutions has appointed Jonathan Arnold as vice president and general manager, Sterile Technologies, effective immediately.
Catalent’s sterile technologies include blow/fill/seal capabilities and an array of injectable options, which help maximise the accuracy of sterile dosage forms and improve the quality and supply of treatments for the global pharmaceutical industry. Arnold will be located at Catalent’s corporate headquarters in Somerset, NJ, US.
Barry Littlejohns, Catalent’s president, Medication Delivery Solutions, said: ‘We are pleased to welcome Jonathan back to Catalent. We are intent on building upon Catalent’s extensive blow/fill/seal and injectable capabilities to become a leading global partner for biologic, vaccine and liquid dose form innovators worldwide.’
Arnold comes to Catalent with 20 years of experience serving the pharmaceutical and biotech industry with contract manufacturing and service solutions. His most recent role was chief procurement officer and vice president global supply chain for Patheon International.
Prior to this, Arnold was export/customer development manager for RP Scherer UK, now part of Catalent.
Jonathan Arnold returns to Catalent
As vice president and general manager of sterile technologies
You may also like
Manufacturing
![Catalent launches ten-month gene-to-drug substance programme for complex biologics]()
Catalent launches ten-month gene-to-drug substance programme for complex biologics
The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Manufacturing
![Codis acquires Catalent's Nottingham site to become Europe's leading end-to-end spray dry provider]()
Codis acquires Catalent's Nottingham site to become Europe's leading end-to-end spray dry provider
The deal pairs Nottingham's OSD development and clinical supply expertise with Codis' commercial-scale Haverhill facility, offering pharma partners an integrated ASD development-to-manufacture pathway within a single quality system
Manufacturing
![Ardena acquires Catalent's US oral dose manufacturing facility, adding further bioanalytical services]()
Ardena acquires Catalent's US oral dose manufacturing facility, adding further bioanalytical services
The CRO/CDMO will now integrate its advanced late-stage and small-scale commercial oral drug product manufacturing services with an extended list of bioanalytical services, enhancing its offering to clients in the North American region
Manufacturing
![Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation]()
Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation
Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its large-scale spray drying unit (GEA PSD-4) at its Boston (MA, US) facility
